股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 先瑞達醫療科技控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06669 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 10,000,000,000 | | USD | | 0.00001 | USD | | 100,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.00001 | USD | | 100,000 | ...

Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號 : 6669) N O T I F I C AT I O N L E T T E R Dear non-registered shareholder(s), 24 September 2025 Acotec Scientific Holdings Limited (the "Company") – Notice of Publication of 2025 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the web ...

Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號 : 6669) N O T I F I C AT I O N L E T T E R 24 September 2025 Dear registered shareholders, Acotec Scientific Holdings Limited (the "Company") – Notice of Publication of 2025 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website o ...

Financial Performance - Revenue for the six months ended June 30, 2025, was RMB 351.2 million, representing a year-on-year increase of 20.1% compared to RMB 292.3 million for the same period in 2024[7] - Gross profit for the same period was RMB 260.5 million, up 19.9% from RMB 217.2 million in the previous year[7] - Profit before tax surged to RMB 89.5 million, a significant increase of 124.1% compared to RMB 39.9 million in the prior year[7] - The net profit for the period was RMB 88,577,000, a significant increase of 121.1% compared to RMB 39,957,000 in the prior year[112] - Total comprehensive income for the period was RMB 88,260,000, significantly up from RMB 40,329,000 in the previous year, indicating a year-over-year increase of 118%[114] - Operating profit from core business operations was RMB 95,035,000, up 105.7% from RMB 46,248,000 in the previous year[112] - Revenue from core products AcoArt Orchid® & Dhalia® and AcoArt Tulip® & Litos® generated approximately RMB 175.6 million and RMB 172.9 million, representing year-on-year increases of approximately 0.6% and 46.9% respectively[50] - Other income for the six months ended June 30, 2025, was approximately RMB 27.0 million, a 39.6% increase from RMB 19.3 million in the previous period, mainly due to increased government subsidies[63] Product Development and Innovation - The company has established over 30 product pipelines focused on vascular interventional solutions across four major medical fields[8] - Six products received market approval during the reporting period, enhancing the company's product portfolio and market share[10] - The company registered 2 patents and submitted 4 new patent applications during the reporting period, reflecting ongoing innovation[9] - A strategic partnership with Boston Scientific Group plc was established to enhance product commercialization and development over the next three years[13] - The company is investing in research and development of drug-coated technologies, which are expected to improve treatment outcomes in peripheral artery diseases[21] - The company plans to enhance its product portfolio through strategic acquisitions, targeting complementary technologies to strengthen its competitive edge[21] - The company has a strong R&D team with 66 registered patents and 30 pending patent applications as of June 30, 2025[48] Market Expansion and Strategy - The company has expanded its international presence, with plans to launch ATK DCB and BTK DCB in multiple countries in 2025[13] - Market expansion efforts include entering new regions such as Brazil and Thailand, aiming for a 10% market share in these territories by 2027[21] - The company is focusing on expanding its presence in Europe, with a goal of achieving a 30% increase in sales in that market by 2026[21] - The company plans to continue expanding in both the Chinese and global markets, focusing on product development and utilizing various financing channels to support capital expenditures[83] Regulatory Approvals and Clinical Trials - The AcoArt Verbena® device received approval from the National Medical Products Administration in May 2025, demonstrating a target lesion re-narrowing rate of 13.04% compared to 37.31% in the control group[14] - The company has initiated clinical trial centers in the US and Europe for the AcoArt Litos® product, marking a significant milestone for entry into the US market[15] - Six products received registration approval during the reporting period, including the AcoArt Verbena® and other vascular intervention devices[19] - The company is conducting clinical trials for the lower limb rapamycin DCB, with expected regulatory approval in 2026[36] Financial Position and Resources - The total available financial resources as of June 30, 2025, amounted to approximately RMB 999.7 million, a 15.7% increase from RMB 864.2 million as of December 31, 2024[73] - The total borrowings as of June 30, 2025, were RMB 49.0 million, up from RMB 10.0 million as of December 31, 2024[74] - The capital-to-debt ratio increased from approximately 23.2% as of December 31, 2024, to about 26.6% as of June 30, 2025, primarily due to increased bank loans[74] - The net current assets as of June 30, 2025, were approximately RMB 1,128.0 million, a 4.9% increase from RMB 1,075.8 million as of December 31, 2024[75] Employee and Operational Efficiency - As of June 30, 2025, the total number of employees is 645, with 141 in the R&D team, enhancing talent reserves in various engineering fields[18] - The company aims to reduce production costs by 20% through operational efficiencies and supply chain optimization[21] - Selling and distribution costs for the six months ended June 30, 2025, were approximately RMB 55.8 million, an increase of about 11.6% from RMB 50.0 million in the previous period, mainly due to increased market investments[65] Shareholder Information - As of June 30, 2025, the total number of issued shares of the company is 313,389,171[1] - Boston Scientific Group plc owns 203,702,962 shares, accounting for 65% of the company's equity[1] - The company issued 2,410,000 restricted shares on June 19, 2025, under the restricted share unit plan[1] - The board does not recommend the distribution of an interim dividend for the six months ended June 30, 2025, consistent with the previous year[169]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 先瑞達醫療科技控股有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 第 1 頁 共 10 頁 v 1.1.1 FF301 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06669 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 10,000,000,000 | USD | | 0.00001 | USD | | 100,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | 10,000,000,000 | USD | | 0.00001 | USD | | 10 ...

Summary of Xianruida Medical Conference Call Company Overview - **Company**: Xianruida Medical - **Industry**: Medical Devices, specifically focusing on drug-coated balloons (DCB) and related products Key Financial Performance - **Revenue**: Achieved 351 million yuan in H1 2025, a year-on-year increase of 20.1% [3] - **Net Profit**: Increased by 121% to 88.58 million yuan, with a net profit margin of 25% [2][3] - **Gross Margin**: Maintained at a high level of 74.2% [2][3][25] Product Development and Market Expansion - **Product Approvals**: Over 9 new products approved in 2025, including the first vertebral artery drug balloon [18][27] - **Clinical Trials**: The first Xisha drug balloon is undergoing IDE clinical trials in the US [2][4] - **International Expansion**: Registered in over 20 countries and initiated 41 new country registration projects [2][4][5] - **Partnerships**: Collaboration with Boston Scientific (波科) for distribution agreements in Europe and joint product development [2][7] Cost Control and Operational Efficiency - **Cost Management**: Reduced R&D expense ratio from 34% to 29% and sales expense ratio from 16% to 11% [2][6] - **Production Optimization**: Implemented measures such as using self-produced raw materials to replace external sourcing, enhancing operational efficiency [6][23] Market Trends and Product Performance - **Peripheral DCB Products**: Contributed 176 million yuan in revenue, indicating rapid growth [3] - **Domestic Market Share**: Achieved a 30% market share in lower limb drug balloon products, with increasing usage in hospitals [2][10] - **Clinical Data**: Vertebral artery drug balloon showed a 12-month target lesion revascularization rate of only 13.04%, significantly lower than the control group [4][15] Future Outlook and Strategic Focus - **Revenue Guidance**: Full-year revenue guidance adjusted to a growth of 20%-25%, with net profit target raised to 120 million yuan [4][24] - **Product Pipeline**: Focus on expanding product lines, enhancing innovation speed, and deepening international partnerships [8][9] - **R&D Investment**: Continued emphasis on R&D to maintain industry leadership and explore new treatment areas [29][30] Regulatory and Market Challenges - **Collective Procurement Impact**: Current gross margin is expected to remain stable despite potential impacts from collective procurement policies [25][26] - **Market Competition**: Despite the emergence of over 20 competitors, the company maintains a leading position in the market [13] Conclusion - **Competitive Advantage**: Xianruida Medical's focus on innovation, market expansion, and operational efficiency positions it well for future growth despite a complex market environment [39][40]

消息面上，先瑞达医疗发布中期业绩，上半年收入3.51亿元人民币，同比增加20.1%；期内溢利8857.7 万元，同比增加121.7%。此外，公司收到中国国家药品监督管理局对外周可控机械解脱带纤维毛弹簧 圈的注册批准。该产品用于外周血管的动脉瘤、动静脉畸形和动静脉瘘的填塞。公司将适时在中国开展 营销活动。 公开资料显示，2022年12月，先瑞达医疗发布公告称，波士顿科学向公司先瑞达发起要约收购，以每股 20港元的价格交易先瑞达不超过65%股份的多数股权，预计交易金额约为5.23亿美元，完成交易后，波 科成为先瑞达医疗的控股公司。2023年7月，双方签订了合作框架协议和服务框架协议，双方将在产品 全球商业化、产品制造服务和产品研发等领域开展合作。 先瑞达医疗-B(06669)绩后涨超13%，截至发稿，涨9.81%，报12.42港元，成交额1101.11万港元。 ...

Core Viewpoint - Xianruida Medical-B (06669) experienced a significant stock price increase of over 13% following the release of its interim results, indicating positive market sentiment towards the company's performance and future prospects [1] Financial Performance - The company reported a revenue of 351 million RMB for the first half of the year, representing a year-on-year increase of 20.1% [1] - Net profit for the same period was 88.577 million RMB, showing a substantial year-on-year growth of 121.7% [1] Regulatory Approval - Xianruida Medical received registration approval from the National Medical Products Administration of China for its peripheral controllable mechanical release fiber spring ring, which is intended for use in treating peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas [1] - The company plans to initiate marketing activities in China for this product in a timely manner [1] Strategic Developments - In December 2022, Boston Scientific initiated a takeover bid for Xianruida Medical, offering 20 HKD per share for up to 65% of the company's majority stake, with an estimated transaction value of approximately 523 million USD [1] - In July 2023, both parties signed a cooperation framework agreement and service framework agreement to collaborate on global commercialization, manufacturing services, and product development [1]

Core Insights - The company reported a revenue of 351 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 20.1% [1] - The profit for the period was 88.577 million RMB, which is a significant year-on-year increase of 121.7% [1] - The basic earnings per share were 0.29 RMB [1]

Group 1 - The company reported a revenue of 351 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 20.1% [1] - Gross profit for the same period was 260 million RMB, showing a year-on-year growth of 19.9% [1] - The net profit for the period reached 88.58 million RMB, which is a significant year-on-year increase of 121.7% [1]